Home > Healthcare > Biotechnology > Bioservices > Cell & Gene Therapy Manufacturing Services Market

Cell & Gene Therapy Manufacturing Services Market Trends

Report ID: GMI5689
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Cell & Gene Therapy Manufacturing Services Market Trends

Rising investments in research and development (R&D) activities have had a profound impact on the growth of the cell and gene therapy manufacturing services market. These investments, driven by increasing private equity and capital infusion in the life sciences sector over the past decade, have been instrumental in fueling the expansion of the market.
For instance, according to the dealforma data, the cash flow into cell and gene therapies remained strong, with a total influx of USD 24 billion in 2021. This includes USD 1.6 billion in upfront cash and equity for partnerships and USD 6.7 billion in venture capital. This surge in investment aimed to support the research, with a notable shift towards innovative and personalized treatment approaches are fueling the market growth.
In addition, strategic partnerships and agreements between pharmaceutical companies and CDMOs, and supportive government initiatives and funding for R&D in cell and gene therapies have played a crucial role in propelling the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global cell & gene therapy manufacturing services industry was valued at USD 5.9 billion in 2023 and is projected to record a CAGR of 18.9% between 2024 – 2032, attributed to biotechnological advancements, which hold promise in treating various diseases such as genetic disorders and cancers.

In 2023, the biopharmaceutical companies segment held 69.4% share in the cell and gene therapy manufacturing services market, attributed to their significant investments in R&D, as well as their extensive expertise in drug discovery and development.

North America cell & gene therapy manufacturing services market is anticipated to record a CAGR of 18.1% through 2032, attributed to the regions growing participation in related R&D, rising cancer cases, as well as a large number of contract development manufacturing organizations.

Catalent, Inc., Charles River Laboratories International, Inc., Merck KGaA, Miltenyi Bioindustry (Miltenyi Biotec), Samsung Biologics, and Takara Bio Inc.